MAPT and Alzheimer disease: The accurate and early diagnosis of AD relies on detecting the core pathophysiological biomarkers of the disease—amyloid-beta (A), tau (T), and neurodegeneration (N) [9,27], although additional biomarkers are also emerging [7].